Richard D Kensinger Deceased524 W Graisbury Ave, Audubon, NJ 08106

2004018, Sep 16, 2004

Mar 9, 2004

10/796707

Cara-Lynne Schengrund - Hummelstown PA, US
Richard Kensinger - Cresco PA, US
Andrew Rosa Borges - Hershey PA, US

C07H005/04
A61K031/715

514/054000, 536/018700

The present invention relates to compositions and methods for inhibiting the interaction of a ligand and receptor. In particular, compositions are methods are provided for inhibition of interaction between a virus, especially HIV, and a receptor. Inhibition of such ligand/receptor interaction is advantageous in inhibiting infection of a cell with a virus. Further, an inhibitor of ligand/receptor interaction serves as a standard in assays of inhibition in vitro or in vivo. In a particular embodiment, a composition according to the invention includes a compound having the formula: [(X)—(Y)]-Z where X is and where Q1 and Q2 are each independently H, a bond to Y, or a bond to Z, where at least one of Q1 or Q2 is a bond to Y or a bond to Z; where R1, R4, R6 and R8 are each H; R2, R3, and R5 are each independently OH, OSO3D, or OPO3D, and R7 is CH20H, CH2OSO3D or CH2OPO3D; where D is H or a cation selected from the group consisting of: alkali metal cations, alkaline earth metal cations, ammonium cations, quaternary ammonium cations and amine cations; and where at least one of R2, R3, R5 and R7 is a sulfur or phosphate containing group; where Y is an optional linker, Z is a multivalent support, and p is an integer in the range of 1-2000 inclusive.

2021040, Dec 30, 2021

Sep 10, 2021

17/471825

- Swiftwater PA, US
- Seongnam-si, KR
Hun KIM - Suwon-si, KR
Sunghyun KIM - Yongin-si, KR
Jinhwan SHIN - Seoul, KR
Robert HOPFER - Roaring Brook Township PA, US
Richard D. KENSINGER - Henryville PA, US
Moe KYAW - Swiftwater PA, US
Philippe TALAGA - Lyon Cedex 07, FR

A61K 39/09

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of conjugated to either tetanus toxoid (TT) or CRM, wherein the serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against infection or disease in a subject.

2021007, Mar 18, 2021

Feb 4, 2019

16/966584

- Swiftwater PA, US
- Seongnam-si, Gyeonggi-do, KR
Hun KIM - Suwon-si, Gyeonggi-do, KR
Sunghyun KIM - Yongin-si, Gyeonggi-do, KR
Jinhwan SHIN - Seoul, KR
Robert HOPFER - Roaring Brook Township PA, US
Richard D. KENSINGER - Henryville PA, US
Moe KYAW - Swiftwater PA, US
Philippe TALAGA - Lyon Cedex 07, FR

A61K 39/09

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of conjugated to either tetanus toxoid (TT) or CRM, wherein the serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of two of serotypes 1, 3, and 5 and one or both of serotypes 15B and 22F are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against infection or disease in a subject.

2020036, Nov 19, 2020

Feb 4, 2019

16/966552

- Swiftwater PA, US
- Seongnam-si, Gyeonggi-do, KR
Hun KIM - Suwon-si, Gyeonggi-do, KR
Sunghyun KIM - Yongin-si, Gyeonggi-do, KR
Jinhwan SHIN - Seoul, KR
Robert HOPFER - Roaring Brook Township PA, US
Richard D. KENSINGER - Henryville PA, US
Moe KYAW - Swiftwater PA, US
Philippe TALAGA - Lyon Cedex 07, FR

A61K 39/09

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 21 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of conjugated to either tetanus toxoid (TT) or CRM, wherein the serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11 A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, where the capsular polysaccharides of serotypes two of serotypes 1, 3, and 5 are conjugated to TT and the remaining capsular polysaccharides are conjugated to CRM. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against infection or disease in a subject.

2020023, Jul 30, 2020

Aug 4, 2017

16/322726

- Swiftwater PA, US
- Seongnam-si, Gyeonggi-do, KR
Dongsoo HAM - Suwon-si, Gyeonggi-do, KR
Hun KIM - Suwon-si, Gyeonggi-do, KR
Jinhwan SHIN - Seoul, KR
Robert HOPFER - Roaring Brook Township PA, US
Richard D. KENSINGER - Henryville PA, US
Moe KYAW - Swiftwater PA, US
Eric DESAUZIERS - Lyon, FR
Clotilde EL GUERCHE SEBLAIN - Lyon, FR
Philippe TALAGA - Lyon, FR

A61K 39/09
A61K 39/116
A61K 39/385
A61K 39/39
A61K 47/64

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 20 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of conjugated to either tetanus toxoid or CRM, wherein the serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRMig7, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against infection or disease in a subject.

2020023, Jul 23, 2020

Aug 4, 2017

16/322698

- Swiftwater PA, US
- Seongnam-si, Gyeonggi-do, KR
Dongsoo HAM - Suwon-si, Gyeonggi-do, KR
Hun KIM - Suwon-si, Gyeonggi-do, KR
Jinhwan SHIN - Seoul, KR
Robert HOPFER - Roaring Brook Township PA, US
Richard D. KENSINGER - Henryville PA, US
Moe KYAW - Swiftwater PA, US
Eric DESAUZIERS - Lyon, FR
Clotilde EL GUERCHE SEBLAIN - Lyon, FR
Philippe TALAGA - Lyon, FR

A61K 39/385
A61K 39/09
A61K 39/39
A61K 47/64
A61P 31/04

Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 16 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of conjugated to either tetanus toxoid or CRM, wherein the serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 12F, 14, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRM, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against infection or disease in a subject.